CTLA4 and cancer: This has culminated with the approval of anti-Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) and Programmed Death (PD)-1/PD-Ligand 1 monoclonal antibodies (mAbs) and CD19-targeted Chimeric Antigen Receptor (CAR)-T-cell infusions as frontline therapies for a variety of cancers.